Automated Solid Phase Extraction of Benzodiazepines from Urine using the Gilson GX-274 ASPEC™

Introduction

This application note information was performed by Phenomenex (www.phenomenex.com) and referenced in application note #19714.

Central Nervous System (CNS) depressants can be used to introduce calm and induce sleep. Benzodiazepines are considered CNS depressants that are used in relieving anxiety, insomnia, and panic attacks; however, there has been reported misuse by mixing benzodiazepines with alcohol or opiates. Currently, 35 benzodiazepines are internationally regulated (source: http://www.emcdda.europa.eu/publications/drug-profiles/benzodiazepine).

Positive identification of benzodiazepines using a confirmatory method of analysis is critical to correctly identifying patients using these pharmaceuticals. Simple screening tests have historically produced false positive results (source: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2728940/).

This application note discusses a simple SPE urine extraction using the Gilson GX-274 ASPEC (see Figure 1) prior to LC/MS-MS to confirm the presence of spiked benzodiazepine analytes.

Figure 1. Image of the Gilson GX-274 ASPEC System
Materials & Methods

SPE Materials:

SPE Cartridges: Phenomenex Strata™ X-Drug N 100u Polymeric Reversed Phase 100 mg / 6 mL

SPE Solutions:
- Wash: Acetonitrile:Water (20:80)
- Elute: Ethyl Acetate:Isopropyl Alcohol (85:15)

Pre-Sample Treatment:
1. Samples were spiked @ 300 ng/mL with 15 benzodiazepine analytes
2. For each 2mL urine sample, add 1mL beta-glucuronidase (contains 5,000 F units/mL Patella vulgata in 100mM acetate buffer(pH 5.0))
3. Mix/vortex
4. Hydrolyze for 3 hours at 60ºC
5. Let cool
6. Add 1mL 100mM Phosphate buffer (pH 6.0)
7. Centrifuge for 5 minutes at 5000 rpm and discard pellet
8. Load directly onto SPE cartridge - NO CONDITIONING REQUIRED

SPE Method:
1. Load 4 mL of pre-treated sample onto SPE cartridge at 3 mL/min
2. Wash with 2 mL solution at 6 mL/min
3. Dry for 10 minutes at 7-15 psi regulated gas (nitrogen, argon, or purified air)
4. Elute SPE cartridge with 2 mL solution at 3 mL/min

Figure 2. TRILUTION® LH Benzodiazepine Solid Phase Extraction Method Using the Gilson GX-274 ASPEC™ System

Final Sample Treatment Prior to Analysis:
1. Evaporate SPE eluent under a stream of nitrogen gas at 50ºC
2. Reconstitute with 1mL of 35% Methanol
3. Inject 5 µL on LC/MS-MS @ amu (ambient)
Analytical LC/MS-MS Materials:

HPLC System
  Binary Gradient Mobile Phase Pumps
  MS-MS Detection: API 3000

Mobile Phase:
  A: 0.1% Formic Acid
  B: 0.1% Formic Acid in Methanol

Column: Phenomenex Kinetex™ 2.6u C18 100A, 50 x 2.1 mm ID

Analytical HPLC Method:

Mobile Phase Gradient:

<table>
<thead>
<tr>
<th>Step No.</th>
<th>Time (min)</th>
<th>Pct A</th>
<th>Pct B</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>0</td>
<td>65</td>
<td>35</td>
</tr>
<tr>
<td>2</td>
<td>4</td>
<td>5</td>
<td>95</td>
</tr>
<tr>
<td>3</td>
<td>4.01</td>
<td>65</td>
<td>35</td>
</tr>
<tr>
<td>4</td>
<td>7</td>
<td>65</td>
<td>35</td>
</tr>
</tbody>
</table>

Flow rate: 300 µL/min

Column Temperature: ambient

Detection: Source: Cur-11, CAD-12, IS-4500, Tem-450, NEB-12
  Dwell: 25ms
  Polarity: Positive
## Results

**Figure 3.** Example Chromatogram of Extracted Benzodiazepines from Urine

<table>
<thead>
<tr>
<th>Peak #/Analyte</th>
<th>Mass Range 1</th>
<th>Mass Range 2</th>
<th>% Recovery</th>
<th>% RSD (n=3)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 / a-Hydroxyalprazolam</td>
<td>325.4&gt;279.2</td>
<td>325.4&gt;204.9</td>
<td>92.4</td>
<td>10.6</td>
</tr>
<tr>
<td>2 / Oxazepam-D5</td>
<td>292.3&gt;246.3</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>3 / Oxazepam</td>
<td>287.1&gt;241.1</td>
<td>287.1&gt;268.9</td>
<td>105.3</td>
<td>5.6</td>
</tr>
<tr>
<td>4 / Alprazolam-D5</td>
<td>314.2&gt;210.2</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>5 / Alprazolam</td>
<td>309.1&gt;205.1</td>
<td>309.1&gt;281.1</td>
<td>98.4</td>
<td>2.1</td>
</tr>
<tr>
<td>6 / Nordiazepam-D5</td>
<td>276.3&gt;140.1</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>7 / Nordiazepam</td>
<td>271.4&gt;140.3</td>
<td>271.3&gt;164.9</td>
<td>103.7</td>
<td>3.7</td>
</tr>
<tr>
<td>8 / Lorazepam-D4</td>
<td>325.1&gt;279.2</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>9 / Lorazepam</td>
<td>321.3&gt;275.3</td>
<td>321.3&gt;239.1</td>
<td>101.1</td>
<td>1.0</td>
</tr>
<tr>
<td>10 / Clonazepam-D4</td>
<td>320.1&gt;274.1</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>11 / Clonazepam</td>
<td>316.3&gt;270.3</td>
<td>316.3&gt;214</td>
<td>99.6</td>
<td>0.5</td>
</tr>
<tr>
<td>12 / Temazepam-D5</td>
<td>306.3&gt;260.2</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>13 / Temazepam</td>
<td>301.3&gt;255.2</td>
<td>301.3&gt;180.1</td>
<td>104.6</td>
<td>3.9</td>
</tr>
<tr>
<td>14 / Diazepam-D5</td>
<td>290.2&gt;154.2</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>15 / Diazepam</td>
<td>285.3&gt;193.2</td>
<td>285.3&gt;154.2</td>
<td>101.1</td>
<td>1.0</td>
</tr>
</tbody>
</table>
Summary

Automated Solid Phase Extraction (SPE) prior to LC/MS-MS analysis of benzodiazepines in urine provides a confirmatory test for the positive or negative presence of these CNS depressants over simple screening tests that have had history of false positive results. This application involves three simple SPE steps, saving even more time by not requiring the general SPE cartridge condition steps or multiple wash steps.

Fast LC/MS-MS analysis in under five minutes creates further efficiency for benzodiazepine analysis. Acceptable resulting recoveries show with high confidence that sample analysis of 15 benzodiazepine analytes from one urine sample is possible with confirmatory results.

References

Phenomenex Application Note 19714: Benzodiazepines from urine using Strata-X-Drug N on a Kinetex C18 2.6μm, 50x2.1mm

Phenomenex Application Note: Benzodiazepines from urine using Strata-X-Drug N on a Kinetex C18 2.6μm, 50x2.1mm


http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2728940/